These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27646333)

  • 21. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
    Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
    Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
    Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.
    Kang HM; Lee SJ; Kim CG; Chung EJ; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.
    Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F
    Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion.
    Manousaridis K; Peter S; Mennel S
    Int Ophthalmol; 2017 Feb; 37(1):47-53. PubMed ID: 27043320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
    Saito M; Iida T; Kano M
    Am J Ophthalmol; 2012 Mar; 153(3):504-514.e1. PubMed ID: 22078902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural and functional assessment after intravitreal injection of ranibizumab in diabetic macular edema.
    Fu Y; Wang P; Meng X; Du Z; Wang D
    Doc Ophthalmol; 2017 Dec; 135(3):165-173. PubMed ID: 28756595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
    Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
    Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
    Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
    Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
    Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
    Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
    Chang LK; Spaide RF; Klancnik JM; Sorenson J; Slakter JS; Freund KB; Yannuzzi LA; Tseng JJ; Klein R
    Retina; 2011 May; 31(5):821-8. PubMed ID: 21317833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
    Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intravitreal ranibizumab injection for the treatment of idiopathic choroidal neovascularisation in young patients].
    Ouhadj O; Degheb N; Idir S; Nebab A; Nouri MT
    J Fr Ophtalmol; 2012 Sep; 35(7):514-22. PubMed ID: 22789650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
    Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.